ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
BioAge Labs Inc

BioAge Labs Inc (BIOA)

4.28
-0.31
(-6.75%)
終了 12月14日 6:00AM
4.2995
0.0195
(0.46%)
取引時間後: 9:52AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
4.2995
買値
4.25
売値
4.30
出来高
660,670
4.24 日の範囲 4.7883
4.23 52 週間の範囲 26.62
時価総額
前日終値
4.59
始値
4.66
最終取引時間
財務取引量
US$ 2,956,333
VWAP
4.4747
平均取引量 (3 か月)
600,747
発行済株式数
35,848,738
配当利回り
-
PER
-2.41
1 株当たり利益 (EPS)
-1.78
歳入
-
純利益
-63.85M

BioAge Labs Inc について

BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Newark, Delaware, USA
設立
-
BioAge Labs Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker BIOA. The last closing price for BioAge Labs was US$4.59. Over the last year, BioAge Labs shares have traded in a share price range of US$ 4.23 to US$ 26.62.

BioAge Labs currently has 35,848,738 shares in issue. The market capitalisation of BioAge Labs is US$164.55 million. BioAge Labs has a price to earnings ratio (PE ratio) of -2.41.

BIOA 最新ニュース

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...

BioAge Labs to Present at Jefferies London Healthcare Conference

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

BioAge Labs Announces Pricing of Upsized Initial Public Offering

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-14.2505-76.822102425918.5520.374.2332081655.54386015CS
4-15.7005-78.50252020.374.239713347.78403856CS
12-18.2005-80.891111111122.526.624.2360074713.76164727CS
26-18.2005-80.891111111122.526.624.2360074713.76164727CS
52-18.2005-80.891111111122.526.624.2360074713.76164727CS
156-18.2005-80.891111111122.526.624.2360074713.76164727CS
260-18.2005-80.891111111122.526.624.2360074713.76164727CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
WKEYWISeKey International Holdings AG
US$ 7.84
(139.02%)
75.5M
IPHAInnate Pharma SA
US$ 3.00
(93.55%)
13.59M
AVLDirexion Daily AVGO Bull 2X Shares
US$ 33.67
(48.92%)
642.41k
LOOPLoop Industries Inc
US$ 1.8092
(47.09%)
82.11M
AVGXDefiance Daily Target 2X Long AVGO ETF
US$ 31.49
(46.67%)
3.42M
RPTXRepare Therapeutics Inc
US$ 1.765
(-55.54%)
4.7M
INOInovio Pharmaceuticals Inc New
US$ 2.31
(-38.56%)
9.86M
XXII22nd Century Group Inc
US$ 0.048
(-34.69%)
42.23M
FLGCFlora Growth Corporation
US$ 1.30
(-34.34%)
4.14M
WTOUTime Limited
US$ 0.281
(-32.74%)
3.79M
NVDANVIDIA Corporation
US$ 134.25
(-2.25%)
228.17M
SOUNSoundHound AI Inc
US$ 16.905
(23.66%)
158.74M
TRUGTruGolf Holdings Inc
US$ 0.6794
(30.93%)
138.19M
RGTIRigetti Computing Inc
US$ 7.155
(19.85%)
122.67M
AVGOBroadcom Inc
US$ 224.80
(24.43%)
117.74M

最近閲覧した銘柄

Delayed Upgrade Clock